Product Detail


Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Cas No. 1455358-06-1, 1-(tert-butyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one

  • 1455358-06-1

  • C11H14N2O

  • 190.24

  • 1.149±0.06

  • Migraine

  • Ubrogepant

  • 12/22/2041 (Ubrogepant)

  • CGRP



As an oral calcitonin gene-related peptide (CGRP) receptor antagonist, Ubrogepant offers fast-acting, effective relief for acute migraines without the typical adverse effects of triptans. This novel approach paves the way for a new era in migraine management, providing patients with a much-needed alternative. By incorporating Ubrogepant into your pharmaceutical portfolio, you can make a significant impact on improving the lives of migraine sufferers and advance neurological care.